India’s Cadila, Swedish NovaSAID To Collaborate On Developing Global Drugs
This article was originally published in PharmAsia News
Executive Summary
Cadila Pharmaceuticals and NovaSAID signed a co-development agreement giving the India drug maker exclusive rights to develop and market the Swedish firm's drugs in Africa, India and the Middle East.